Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 9, 22 | -0.12
Increased by
+73.33%
|
-0.28
Increased by
+204.08%
|
Aug 11, 22 | -4.34
Decreased by
-804.17%
|
-0.37
Decreased by
-2.90 K%
|
May 16, 22 | -0.36
Increased by
+21.74%
|
-0.38
Increased by
+13.85%
|
Mar 15, 22 | -0.36
Increased by
+50.68%
|
-0.44
Increased by
+41.32%
|
Nov 8, 21 | -0.45
Increased by
+22.41%
|
-0.45 |
Aug 12, 21 | -0.48
Increased by
+38.46%
|
-0.47
Decreased by
-4.53%
|
May 6, 21 | -0.46
Increased by
+86.89%
|
-0.49
Increased by
+12.49%
|
Mar 16, 21 | -0.73
Decreased by
-62.22%
|
-0.64
Decreased by
-21.97%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 0.00
Decreased by
N/A%
|
-4.02 M
Increased by
+57.42%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 22 | 0.00
Decreased by
N/A%
|
-98.26 M
Decreased by
-858.52%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 22 | 0.00
Decreased by
N/A%
|
-7.94 M
Increased by
+17.91%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 21 | 0.00
Decreased by
N/A%
|
-7.76 M
Increased by
+49.62%
|
Decreased by
N/A%
Decreased by
N/A%
|
Sep 30, 21 | 0.00
Decreased by
N/A%
|
-9.45 M
Increased by
+23.26%
|
Decreased by
N/A%
Decreased by
N/A%
|
Jun 30, 21 | 0.00
Decreased by
N/A%
|
-10.25 M
Increased by
+37.37%
|
Decreased by
N/A%
Decreased by
N/A%
|
Mar 31, 21 | 0.00
Decreased by
N/A%
|
-9.67 M
Decreased by
-2.86%
|
Decreased by
N/A%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-15.39 M
Decreased by
-17.75%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.